National Heart, Lung, and Blood Institute (NHLBI): Anemia trials

The registry lists 44 Anemia studies with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor. 1 are open to participants now and 14 have results posted.

Phase 1 8Phase 2 22Phase 3 4No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Screening for Hematology Branch ProtocolsEnrolling by invitationNCT00001620
• Treatment of Refractory Diamond-Blackfan Anemia With EltrombopagCompletedNCT04269889Phase 1/2Results posted
• Extended Dosing With Eltrombopag for Severe Aplastic AnemiaCompletedNCT01891994Phase 2Results posted
• Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic AnemiaCompletedNCT01193283Phase 1/2Results posted
• A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic AnemiaCompletedNCT01187017Phase 1/2Results posted
• Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA TreatmentCompletedNCT00944749Phase 2Results posted
• A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia PatientsCompletedNCT00922883Phase 2Results posted
• Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)CompletedNCT00890396Results posted
• Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic SyndromeCompletedNCT00604201Phase 2Results posted
• Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaCompletedNCT00260689Phase 2Results posted
• Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaCompletedNCT00229619Phase 2Results posted
• Alemtuzumab to Treat Severe Aplastic AnemiaCompletedNCT00195624Phase 2Results posted
• Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic AnemiaCompletedNCT00065260Phase 2Results posted
• Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell AnemiaCompletedNCT00006400Phase 3Results posted
• A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureTerminatedNCT00001962Phase 2Results posted
• Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive TherapyCompletedNCT04436380
• Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive TherapyCompletedNCT04436367
• Carbon Monoxide Levels and Sickle Cell Disease SeverityCompletedNCT01547793
• Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood DisordersCompletedNCT01316796Phase 1
• Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic AnemiaCompletedNCT00767650
• Blood Cell Collection for Future Use in Individuals With Fanconi AnemiaCompletedNCT00271089Not applicable
• Improving Immunosuppressive Treatment for Patients With Severe Aplastic AnemiaCompletedNCT00061360Phase 2
• Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic AnemiaCompletedNCT00050115
• Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP IICompletedNCT00037388
• Induction of Stable Chimerism for Sickle Cell AnemiaCompletedNCT00029393Phase 2
• Cord Blood Transplantation for Sickle Cell Anemia and ThalassemiaCompletedNCT00029380Phase 2
• Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary HypertensionCompletedNCT00023296Phase 1
• Stem Cell Mobilization Potential in Patients With Aplastic Anemia in RemissionCompletedNCT00011830Phase 1
• Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan AnemiaCompletedNCT00011505Phase 2
• Stroke Prevention in Sickle Cell Anemia (STOP 2)CompletedNCT00006182Phase 3
• Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic AnemiaCompletedNCT00005935Phase 2
• Aplastic Anemia Epidemiology: Incidence and Case-controlCompletedNCT00005682
• Anemia and Surgery: Indications For TransfusionCompletedNCT00005308
• Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study DataCompletedNCT00005307
• Drug Etiology of Aplastic Anemia and Related DyscrasiasCompletedNCT00005302
• Combination Therapy of Severe Aplastic AnemiaCompletedNCT00001964Phase 2
• Medical Treatment for Diamond Blackfan AnemiaCompletedNCT00001749Phase 2
• Comparing Therapies for the Treatment of Severe Aplastic AnemiaCompletedNCT00001626Phase 2
• Gene Therapy for the Treatment of Fanconi's Anemia Type CCompletedNCT00001399Phase 1
• Stem Cell Factor Medication for Aplastic AnemiaCompletedNCT00001398Phase 1
• Cord Blood Stem Cell Transplantation Study (COBLT)CompletedNCT00000603Phase 2
• Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)CompletedNCT00000602Phase 2
• Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic DisordersCompletedNCT00000597Phase 3
• Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)CompletedNCT00000586Phase 3